Novo Nordisk A/S Common Stock (NY:NVO)

41.02 -1.94 (-4.52%)

Official Closing Price Updated: 4:10 PM EDT, Jun 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗

June 07, 2026

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Via The Motley Fool

Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗

June 06, 2026

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

Via The Motley Fool

Topics Intellectual Property

CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗

June 05, 2026

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

Via The Motley Fool

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗

June 04, 2026

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

Via The Motley Fool

Topics Intellectual Property

Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗

June 03, 2026

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

Via The Motley Fool

Here's What I Think Is Really Going on With Novo Nordisk Stock ↗

June 03, 2026

There is light at the end of the tunnel.

Via The Motley Fool

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗

June 03, 2026

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Via The Motley Fool

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗

June 02, 2026

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

Via MarketBeat

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗

June 02, 2026

An upcoming trial result could change how investors think about the weight-loss drug market.

Via The Motley Fool

Lexicon (LXRX) Q1 2026 Earnings Transcript ↗

June 01, 2026

Lexicon (LXRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Is Eli Lilly Starting an Nvidia-Style Run? ↗

June 01, 2026

Lilly shares soared more than 18% in May.

Via The Motley Fool

Topics Artificial Intelligence

5 Best Growth Stocks for the Next 10 Years ↗

May 31, 2026

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Via MarketBeat

Topics Artificial Intelligence Economy

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗

May 30, 2026

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

Via The Motley Fool

The Smartest Growth Stocks to Buy With $2,000 Right Now ↗

May 30, 2026

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

Via The Motley Fool

Topics Artificial Intelligence

Stock Split Watch: Is Eli Lilly Next? ↗

May 30, 2026

Lilly has split its stock in the past.

Via The Motley Fool

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗

May 28, 2026

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Via The Motley Fool

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗

May 28, 2026

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Via MarketBeat

Topics Earnings

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗

May 27, 2026

There is no reason to panic just yet.

Via The Motley Fool

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗

May 27, 2026

Eli Lilly's fundamentals matter more than Trump's stock purchases.

Via The Motley Fool

Topics Government

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗

May 26, 2026

These players are seeing exciting results in clinical trials.

Via The Motley Fool

Don't Buy Viking Therapeutics Stock Until You Read This ↗

May 25, 2026

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Via The Motley Fool

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗

May 25, 2026

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

The Silver Lining of Last Week's Hims & Hers Earnings Miss ↗

May 21, 2026

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Via MarketBeat

Topics Earnings

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products

From MarketNewsUpdates.com

Via GlobeNewswire

Could Viking Therapeutics Be the Next Eli Lilly? ↗

May 21, 2026

Demand for weight loss drugs may fuel growth for more than one player.

Via The Motley Fool

Best Weight Loss Drug Stocks to Buy in 2026 ↗

May 20, 2026

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Via The Motley Fool

Topics Intellectual Property

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗

May 20, 2026

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Via MarketBeat

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗

May 18, 2026

This dark horse in the weight loss drug race is worth keeping on your watch list.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.